US Patent 7,235,567 (Drug) Scope, Claims, and US Patent Landscape
What does US 7,235,567 claim cover?
US Patent 7,235,567 claims a specific crystalline polymorph (Form 1) of a drug “Compound 2,” defined by powder X-ray diffraction (PXRD) peak location criteria and a differential scanning calorimetry (DSC) profile, and then extends coverage to pharmaceutical formulations containing that polymorph and to a purified form of the polymorph.
The claims as provided are composition-and-identification claims anchored to solid-state characterization rather than to a particular method of making or using.
What is the claimed polymorph definition (Claim 1)?
Claim 1 defines:
- Crystalline polymorph: “Form 1”
- Substance: “Compound 2” (structural formula is referenced but not reproduced in the prompt)
- Solid-state characterization: a PXRD pattern “exhibits characteristic peak locations” at:
- 11.2° 2θ
- 16.4° 2θ
- 19.2° 2θ
- 21.0° 2θ
Scope implication: Any crystalline material that is (i) Compound 2 and (ii) Form 1 meeting the claimed PXRD peak location set falls within Claim 1, even if the claim does not require additional peaks or a complete pattern match.
How do dependent claims narrow or expand PXRD coverage (Claims 2-4)?
? Claim 2
Claim 2 further narrows Claim 1 by adding additional “characteristic peak locations” at:
- 9.9° 2θ
- 11.2° 2θ
- 16.4° 2θ
- 19.2° 2θ
- 21.0° 2θ
- 22.1° 2θ
- 23.7° 2θ
- 26.7° 2θ
Scope implication: The legal boundary tightens to polymorphs showing an expanded signature that includes the additional peaks (not just the four peaks in Claim 1).
? Claim 3
Claim 3 tightens further (or changes the evidentiary signature) by listing an even broader set of characteristic peaks at:
- 9.9° 2θ
- 11.2° 2θ
- 12.6° 2θ
- 14.5° 2θ
- 16.4° 2θ
- 19.2° 2θ
- 21.0° 2θ
- 22.1° 2θ
- 23.7° 2θ
- 26.7° 2θ
- 28.2° 2θ
- 30.8° 2θ
Scope implication: This adds more numeric constraints and increases the chance that invalid non-conforming forms (or differently processed material) fall outside the claim’s literal PXRD set.
? Claim 4
Claim 4 uses a “substantially the same” formulation:
- PXRD pattern is “substantially the same as the powder X-ray diffraction pattern shown in FIG. 1.”
Scope implication: Claim 4 is the broadest in terms of tolerance because it relies on a reference pattern rather than only a fixed set of peaks. “Substantially the same” typically creates room for argument over peak shifts, intensities, and missing minor peaks.
Does the patent also anchor Form 1 to thermal behavior (Claim 5)?
Claim 5 defines the same crystalline polymorph Form 1 of Compound 2 but anchors it to DSC:
- “exhibits a differential scanning calorimetry pattern substantially the same as the DSC pattern shown in FIG. 3.”
Scope implication: This introduces an alternative characterization gate. In enforcement, the patentee can argue that a competitor’s Form 1 that matches PXRD also matches thermal behavior, or that matching DSC alone should demonstrate the polymorph identity if the evidentiary burden is satisfied.
Does the patent cover formulations and “purified” material (Claims 6-7)?
? Claim 6
Claim 6 is a standard downstream product claim:
- “A pharmaceutical composition comprising”
- the crystalline polymorph Form 1 of Compound 2 (as in Claim 1)
- at least one excipient or carrier
Scope implication: This captures marketed and pipeline dosage forms, provided they contain the claimed polymorph. It does not require any specific dosage form type in the prompt.
? Claim 7
Claim 7 is an additional product-quality limitation:
- “A purified form of the crystalline polymorph Form 1 of Compound 2 of claim 1.”
Scope implication: This targets higher-purity lots, polymorph-enriched material, and potentially intermediates or API material where the purification process yields a “purified form” falling within the polymorph identity criteria.
How would infringement arguments typically be structured?
Based on the claim set, enforcement would likely proceed as follows:
- Identify the active ingredient: establish it is “Compound 2” (not another compound).
- Identify the polymorph: test the candidate material’s PXRD and compare to the claimed peak locations (Claims 1-3) and/or reference to FIG. 1 (“substantially the same,” Claim 4).
- Corroborate identity: use DSC comparison to FIG. 3 (“substantially the same,” Claim 5).
- Downstream reach: if a competitor sells a dosage form, test the solid-state form in the finished composition (Claim 6).
- Purity framing: if a competitor supplies API or isolates, test whether it is “purified form” and whether it still matches Form 1 identity requirements (Claim 7).
Because the claims are identity-defined, the central technical question is whether the accused material is literally or substantially within the claimed polymorph signature.
What is the technical scope boundary created by the PXRD peak lists?
The PXRD-based claim language creates a measurable boundary. The key legal and technical consequences:
- Literal peak-location constraints (Claims 1-3): If a competitor’s Form 1 exhibits the claimed peaks at the specified 2θ positions, it is more likely to be asserted. If peaks shift outside the tolerances normally used in PXRD analysis, claim coverage can narrow.
- Pattern-based flexibility (Claims 4): “Substantially the same” to FIG. 1 can support arguments despite minor deviations in peak intensities or additional low-intensity peaks.
- Thermal corroboration (Claim 5): DSC “substantially the same” to FIG. 3 offers an additional evidentiary pathway tied to the polymorph’s thermal signature.
Claim coverage map (what each claim captures)
| Claim |
What is claimed |
Core defining criteria in prompt |
Practical coverage target |
| 1 |
Polymorph Form 1 of Compound 2 |
PXRD peaks at 11.2, 16.4, 19.2, 21.0 (2θ) |
Baseline polymorph identity |
| 2 |
Subset of Claim 1 |
PXRD peaks at 9.9, 11.2, 16.4, 19.2, 21.0, 22.1, 23.7, 26.7 |
Expanded fingerprint polymorph |
| 3 |
Subset of Claim 1 |
PXRD peaks at 9.9, 11.2, 12.6, 14.5, 16.4, 19.2, 21.0, 22.1, 23.7, 26.7, 28.2, 30.8 |
Most constrained fingerprint list |
| 4 |
Polymorph Form 1 |
PXRD “substantially the same” as FIG. 1 |
Tolerance-driven identity |
| 5 |
Polymorph Form 1 |
DSC “substantially the same” as FIG. 3 |
Thermal signature identity |
| 6 |
Pharmaceutical composition |
Includes Claim 1 polymorph + excipient/carrier |
Finished dosage forms and formulation stage |
| 7 |
Purified form |
Purified Form 1 of Compound 2 (Claim 1) |
API isolation and polymorph-enriched lots |
How does this claim set shape the broader US patent landscape?
On the information provided, US 7,235,567 is a polymorph patent with both:
- form-specific upstream coverage (Form 1 API),
- form-specific downstream coverage (formulations),
- identity confirmation (PXRD and DSC),
- product purity framing (purified form).
In practical landscape terms, this type of claim typically clusters with:
- earlier patents on Compound 2 itself (drug substance synthesis or composition),
- later patents on other polymorphs, solvates, hydrates, amorphous forms, and co-crystals,
- process patents (crystallization routes),
- formulation patents (dosage forms, particle size, release profiles).
However, the prompt does not provide the application family, assignee, filing date, or related US patent numbers. Without those elements, a complete mapped landscape (continuations, divisionals, related grants, Orange Book listings, and litigation status) cannot be produced from the claim text alone.
Given the constraint, the landscape analysis below focuses on scope-driven strategic implications rather than listing specific adjacent patents.
Landscape implications for R&D strategy and freedom-to-operate (FTO)
1) Competitors need to manage polymorph control
A rival can reduce direct risk by ensuring their polymorph is not Form 1 and does not meet the PXRD/DSC identity tests used in the patent. For polymorph-stability systems, the risk is form conversion during manufacturing, milling, drying, storage, or in dosage.
2) “Substantially the same” expands the evidentiary attack surface
Claims 4 and 5 can be leveraged even when a competitor’s PXRD shows minor shifts. This increases the importance of:
- measurement protocol alignment (instrument, wavelength, sample prep),
- explicit comparison to the reference patterns used by the patent.
3) Formulation launch risk is immediate
Claim 6 means that a competitor cannot rely on developing a new formulation unless it demonstrably avoids the Form 1 polymorph identity.
4) API substitution and purification do not automatically avoid liability
Claim 7 captures “purified form” of Form 1. So if purification yields Form 1 and the identity tests are satisfied, supply-side strategies can still fall within coverage.
Key takeaways
- US 7,235,567 is a Form 1 polymorph patent for Compound 2, defined by PXRD peak location sets (Claims 1-3) and reinforced by pattern-based PXRD and DSC identity (“substantially the same”) (Claims 4-5).
- The patent extends to pharmaceutical compositions containing the Form 1 polymorph (Claim 6) and to purified Form 1 API material (Claim 7).
- Scope is controlled by solid-state characterization, so the competitive fault line is whether an accused material is literally within the listed peak sets or is substantially the same as the FIG. 1 PXRD and FIG. 3 DSC reference patterns.
- Landscape actions are driven by polymorph control and stability across manufacturing and product lifecycle, not only by synthesis route changes.
FAQs
What is the core invention protected by US 7,235,567?
A specific crystalline polymorph, Form 1 of Compound 2, defined by PXRD peak positions and DSC profile.
Do the claims require a full PXRD pattern match?
Claims 1-3 use specific peak location sets; Claims 4 and 5 use “substantially the same” comparisons to reference figures.
Can a formulation avoid infringement by changing excipients?
No. Claim 6 covers any pharmaceutical composition that contains the Form 1 polymorph plus at least one excipient or carrier.
Does the patent cover API as well as finished dosage forms?
Yes. Claims 1 and 7 target crystalline Form 1 material (including purified Form 1), while Claim 6 covers compositions.
What tests matter most for enforcement?
PXRD (Claims 1-4) and DSC (Claim 5) against the claimed peak lists or reference patterns.
References
[1] US Patent 7,235,567 (claims provided in prompt).
